Omnicell beat analysts’ revenue expectations by 2.2% last quarter, reporting revenues of $306.9 million, up 18.6% year on year. It was a slower quarter for the company, with EBITDA guidance for ...

Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 17.5% in the afternoon session after the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA ...

Omnicell (OMCL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.03 per share a year ago. These figures ...

Omnicell, Inc. OMCL reported first-quarter 2025 adjusted earnings per share (EPS) of 26 cents compared with 3 cents in the year-ago period. The metric beat the Zacks Consensus Estimate by 62.5% ...

CEO Randall Lipps highlighted strong Q1 2025 performance driven by demand for Omnicell's medication management platform. Key focus areas included market share growth in inpatient and outpatient ...

Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior ...

Wells Fargo upgraded Omnicell (NASDAQ:OMCL) to Overweight from Equal Weight on Wednesday, citing a compelling risk-reward setup in the shares of the Fort Worth, Texas-based vendor of pharmacy ...

FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Omnicell Inc. (OMCL) on Tuesday reported a loss of $7 million in its first quarter. On a per-share basis, the Fort Worth, Texas-based company ...

Omnicell shares fell after the company lowered its guidance due to expected costs and uncertainty from tariffs. The stock slid 15% to $26.01 on Tuesday morning, at one point touching a 52-week low ...